Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Curtis, Andrea J ^a   Marshall, Catherine S ^b   Spelman, Tim ^a,c   Greig, Jane ^d   Elliot, Julian H ^a,b,c   Shanks, Leslie ^d   du Cros, Philipp ^d   Casas, Esther C ^d   da Fonseca, Marcio Silveria ^d   O'Brien, Daniel P ^d,e,f  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e GEELONG HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; AFRICA; ARTICLE; ASIA; CD4 LYMPHOCYTE COUNT; CHRONIC DIARRHEA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISEASE CLASSIFICATION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PENICILLIOSIS; THRUSH; TOXOPLASMOSIS; WASTING SYNDROME; WEIGHT REDUCTION;

ADULT; AFRICA; AGE FACTORS; ANTI-RETROVIRAL AGENTS; ASIA; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; SEVERITY OF ILLNESS INDEX;

BACTERIA (MICROORGANISMS);

EID: 84871451362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052019     Document Type: Article

References (29)

1. World Health Organisation (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. Geneva.
2. Lawn SD, Harries AD, Wood R, (2010) Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 5: 18-26.
3. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20: 2355-2360.
4. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
5. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, et al. (2009) Cause-Specific Mortality and the Contribution of Immune Reconstitution Inflammatory Syndrome in the First 3 Years after Antiretroviral Therapy Initiation in an Urban African Cohort. Clinical Infectious Diseases 49: 965-972.
6. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, et al. (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282: 2220-2226.
7. Ives NJ, Gazzard BG, Easterbrook PJ, (2001) The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. J Infect 42: 134-139.
8. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30Suppl 1: S5-14.
9. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, et al. (2010) AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 24: 1549-1559.
10. Lynen L (2006) Clinical HIV/AIDS Care Guidelines for Resource-poor Settings, Second Edition. Médecins Sans Frontières Operational Centre Brussels. April.
11. World Health Organisation (2006) Antiretroviral therapy for adults and adolescents in resource-limited settings:towards universal access. Geneva: World Health Organisation.
12. World Health Organization (2004) Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva.
13. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, et al. (2005) The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Archives of internal medicine 165: 416-423.
14. Hoover DR, Munoz A, Carey V, Odaka N, Taylor JM, et al. (1991) The unseen sample in cohort studies: estimation of its size and effect. Multicenter AIDS Cohort Study. Statistics in medicine. 10(12): 1993-2003.
15. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. (2009) Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 23: 631-636.
16. World Health Organisation (2011) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva.
17. Kasprowicz VO, Achkar JM, Wilson D, (2011) The tuberculosis and HIV epidemic in South Africa and the KwaZulu-Natal Research Institute for Tuberculosis and HIV. J Infect Dis 204Suppl 4: S1099-1101.
18. World Health Organisation (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children.
19. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278-1286.
20. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428-1434.
21. Sloan DJ, Dedicoat MJ, Lalloo DG, (2009) Treatment of cryptococcal meningitis in resource limited settings. Curr Opin Infect Dis 22: 455-463.
22. World Health Organisation (2011) Global tuberculosis control. World Health Organisation.
23. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, et al. (2007) Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2: e826.
24. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S, (2006) Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. Journal of acquired immune deficiency syndromes 43: 42-46.
25. Fielding K, Grant A, Lewis J, Hayes R, Churchyard G (2012) Individual-level effect of isoniazid preventive therapy on risk of TB: the Thibela TB Study. 19th Conference on Retroviruses and Opportunistic Infections Seattle, USA.
26. UNICEF/WHO (2006) Pneumonia: The forgotten killer of children.
27. Newell M-L, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. The Lancet 364: 1236-1243.
28. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, et al. (1996) Cryptococcosis in human immunodeficiency virus-infected children. The Pediatric infectious disease journal 15: 796-800.
29. Abadi J, Nachman S, Kressel AB, Pirofski L, (1999) Cryptococcosis in children with AIDS. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 28: 309-313.